Document Detail

Laboratory assays and duplex scanning outcomes after symptomatic deep vein thrombosis: preliminary results.
MedLine Citation:
PMID:  8627897     Owner:  NLM     Status:  MEDLINE    
PURPOSE: The purpose of this article was to assess a number of hematologic and fibrinolytic assays at the time of diagnosis of deep vein thrombosis (DVT) and at several intervals over a period of 6 months afterward and to correlate these results with the results of serial duplex scanning.
METHODS: Thirty-five patients (average age 61, range 18 to 82) with acute symptomatic DVT confirmed by duplex scanning were included. On diagnosis, blood was drawn, and plasma levels of tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor (PAI), D-dimer (DD), and tissue factor pathway inhibitor (TFPI) were determined. Duplex scanning and all laboratory assays were repeated 1 week, 1 month, 3 months, and 6 months thereafter.
RESULTS: The rate of DVT complete resolution 6 months after diagnosis was 57%. Whereas plasma levels of PAI were similar throughout the 6-month follow-up period, t-PA increased significantly 1 week after diagnosis and decreased thereafter. Both DD and TFPI levels decreased significantly after diagnosis compared with presentation values. Comparing these assay levels between patients with complete resolution versus partial or no resolution, PAI levels were significantly higher during the first week in patients with poor outcome. Plasma levels of t-PA were higher in cases with good outcome, and DD levels were higher in patients with poor outcome. TFPI levels were similar in both outcome groups.
CONCLUSIONS: Patients with complete DVT resolution on duplex scanning at 6 months had significantly lower levels of PAI on presentation and after 1 week than did those with incomplete lysis. Although differences were not significant, t-PA levels were higher and DD lower in patients with good outcome. Our results suggest that certain plasma fibrinolytic assays might correlate with the outcome of DVT, as assessed by duplex ultrasonography.
J I Arcelus; J A Caprini; K N Hoffman; N Fink; G P Size; J Fareed; D Hoppensteadt
Related Documents :
10212007 - Two instruments to determine activated partial thromboplastin time: implications for he...
1761997 - Heparin and graduated compression stockings in patients undergoing fractured hip surgery.
22541147 - Effect of oxidized regenerated cellulose on the healing of pharyngeal wound: an experim...
12050997 - Prevention of thromboembolic disease after non-cemented hip arthroplasty. a multimodal ...
18173597 - Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report...
17995497 - Post-hysterectomy pelvic fluid collection: is it associated with febrile morbidity?
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Journal of vascular surgery     Volume:  23     ISSN:  0741-5214     ISO Abbreviation:  J. Vasc. Surg.     Publication Date:  1996 Apr 
Date Detail:
Created Date:  1996-06-24     Completed Date:  1996-06-24     Revised Date:  2012-10-03    
Medline Journal Info:
Nlm Unique ID:  8407742     Medline TA:  J Vasc Surg     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  616-21     Citation Subset:  IM    
Department of Surgery, Glenbrook Hospital, Glenview, IL 60025, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Anticoagulants / therapeutic use
Biological Markers / blood
Fibrin Fibrinogen Degradation Products / analysis
Fibrinolytic Agents / blood*
Follow-Up Studies
Lipoproteins / blood
Middle Aged
Plasminogen Activator Inhibitor 1 / blood
Plasminogen Activators / blood
Prospective Studies
Serine Proteinase Inhibitors / blood
Thrombophlebitis / blood*,  drug therapy,  ultrasonography*
Tissue Plasminogen Activator / blood
Treatment Outcome
Ultrasonography, Doppler, Duplex*
Reg. No./Substance:
0/Anticoagulants; 0/Biological Markers; 0/Fibrin Fibrinogen Degradation Products; 0/Fibrinolytic Agents; 0/Lipoproteins; 0/Plasminogen Activator Inhibitor 1; 0/Serine Proteinase Inhibitors; 0/fibrin fragment D; 0/lipoprotein-associated coagulation inhibitor; EC 3.4.21.-/Plasminogen Activators; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Valvular function of peripheral veins after hyperemic dilation.
Next Document:  The changing face of carotid endarterectomy.